Skip to content

Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.

Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in Patients With COVID-19 Associated Acute Respiratory Distress Syndrome (CARDS)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05341687
Acronym
COMPLIECMO
Enrollment
122
Registered
2022-04-22
Start date
2020-01-03
Completion date
2023-05-01
Last updated
2024-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ards, Extracorporeal Membrane Oxygenation, Mechanical Ventilation Pressure High

Brief summary

Mortality of patients with COVID-19 associated acute respiratory distress syndrome (CARDS) treated with veno-venous extra-corporal membrane oxygenation (vv-ECMO) is increasing over time since the beginning of the COVID-19 pandemic. The objectives were to retrospectively describe over the first ten days after vv-ECMO implantation, the ventilatory management of CARDS and to assess the impact of static respiratory system compliance (CRS) on the first day of vv-ECMO on 180-day mortality.

Interventions

OTHERNo applicable

No applicable

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with ARDS secondary to COVID-19 pneumonia requiring ECMO-VV support, hospitalized in the intensive care units of the CHRU of Nancy, Marseille or Bordeaux between 01/03/2020 and 31/12/2021. * Age \> 18 years old

Exclusion criteria

* Respiratory parameters not available on ten first day of VV ECMO implantation. * Patient refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Vital status (dead or alive)Days, 10.according to compliance during the first ten days of VV ECMO implantation

Secondary

MeasureTime frameDescription
Evolution of driving pressureDays, 10after VV-ECMO implantation
Evolution of tidal volumeDays, 10after VV-ECMO implantation
Evolution of PEEPdays, 10after VV-ECMO implantation

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026